Publications

Original articles

1. Zhu, M. and Kyprianou, N. Role of Androgens and the Androgen Receptor in Epithelial-Mesenchymal Transition and Invasion of Prostate Cancer Cells. The FASEB Journal, 24(3):769-777, 2010

2. Sakamoto, S., McCann R.O., Dhir, R. and Kyprianou, N.  Talin1 Promotes Tumor Invasion and Metastasis via Focal Adhesion Signaling and Anoikis Resistance. Cancer Res., 70(5):1885-1895, 2010

3. Zhu, M., Horbinski, C., Garzotto, M., Qian D., Beer, T. and Kyprianou, N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res., 70(20):7992-8002, 2010.

4. Sakamoto, S., Schwarze, S., and Kyprianou, N. Anoikis Disruption of Focal Adhesion-Akt Signaling Impairs Renal Cell Carcinoma. European Urology, 59(5):734-744, 2011.

5.  Zhu, H., Zhao, J., Zhu, B., Collazo, J., Gal, J., Shi, P., Liu, L., Strom, A.L., Lu, X., McCann, R.O., Toborek, M., and Kyprianou, N. EMMPRIN Regulates Cytoskeleton Reorganization and Prostate Cancer Cell Invasion, The Prostate, 72(1):72-81, 2012.

6.  Fiandalo, M., Schwarze, S. R. and Kyprianou, N. Regulation of caspase-8 activity by proteosomal degradation in cancer cells. APOPTOSIS, 18:766-776, 2013.

7.  Collazo, J., Zhu, B., Larkin, S., Pu, H., Koochekpour, S., Martin, S.K, Horbinski, C. and Kyprianou, N. Cofilin regulates cellular invasion responses to TGF-β towards prostate cancer metastasis. Cancer Res.  74(8):2362-2373, 2014.

8.  Hensley, P., Desiniotis A., M., Wang, C., Stromberg A., Chen, C-S and Kyprianou, N. Novel pharmacologic targeting of tight junctions in prostate cancer cells.  PLOS ONE, 9(1):e86238, 2014.

9.   Pu, H., Horbinski, C., Hensley, P., Matuszak, E.A, Atkinson, T. and Kyprianou, N. Poly (ADP) ribose polymerase-1 (PARP-1) regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.  Carcinogenesis, 35(11):2592-601, 2014.

10.  Martin, S. K., Banuelos, C.A., Sadar, M. D. and Kyprianou, N. N-Terminal Targeting of Androgen Receptor Variant Enhances Therapeutic Response of Castration-Resistant Prostate Cancer to Taxanes.  Molecular Oncology, S1574-7891(14)00263-4, 2014.

 

Review articles

  1. Matuszak, E. and Kyprianou, N. Androgen Regulation of Epithelial-Mesenchymal Transition in Prostate Tumorigenesis. Expert Reviews in J. Clinical Endocrinology and Metabolism, 6(3):469-482, 2011.
  2. Desiniotis, A. and Kyprianou, N.  Advances in the Design and Synthesis of Prazosin Derivatives over the Last Ten Years. Expert Opinion in Therapeutic Targets, 15(12):1405-1418, 2011.
  3. Hensley, J.P. and Kyprianou, N. Modeling prostate cancer in mice: Opportunities and Limitations. J. Andrology, 33(2):133-144, 2012.
  4. Fiandalo, M.V. and Kyprianou, N. Caspase Control: Protagonists of Cancer Cell Apoptosis in Experimental Oncology; Special issue on "Apoptosis: four decades later", 34(3):165-175, 2012.
  5. Hendrix, L.N., Hamilton, A.D. and Kyprianou, N. Emerging therapeutics targeting castration resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenhymal transition.  Expert Reviews of Endocrinology and Metabolism, 8 (4): 403-416, 2013.
  6. Larkin, S. and Kyprianou, N. Molecular Signatures in Urologic Tumors Int J Mol Sci. 6,14(9):18421-18436, 2013.
  7. Bilbro, J.M. Mart, M. and Kyprianou, N. Therapeutic Value Novel Quinazoline-Based Compounds in Prostate Cancer. Anticancer Research, 33 (11):4695-4700, 2013.
  8. Khan, B., Collazo, K. and Kyprianou, N. Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer. Int J Biol Sci. 1;10(6):588-595, 2014.
  9. Lacy, J. and Kyprianou, N. A Tale of Two Trials: Impact of 5α-reductase Inhibition on Prostate Cancer. Oncology Letters, 8(4):1391-1396, 2014.
  10. Martin, S.K., Kamelgran, M., and Kyprianou, N. The Cytoskeleton Targeting Value in Prostate Cancer Treatment. Am. J. of Clinical and Exper. Urol, 2(1):15-26, 2014.